LLM finds valid cancer mechanism

A 27B Gemma‑based model trained on transcriptomics and bio text hypothesized that inhibiting CK2 (via silmitasertib) would enhance MHC‑I antigen presentation—making tumors more visible to the immune system. Yale labs tested the prediction and confirmed it in vitro, and are now probing the mechanism and related hypotheses. — If small, domain‑trained LLMs can reliably generate testable, validated biomedical insights, AI will reshape scientific workflow, credit, and regulation while potentially speeding new immunotherapy strategies.